{
    "nct_id": "NCT06400238",
    "official_title": "MATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients With Tumors With Deleterious PTEN Sequencing Result and PTEN Expression by IHC",
    "inclusion_criteria": "* Patients must have met applicable eligibility criteria in the Master MATCH Protocol EAY131/ NCI-2015-00054 prior to registration to treatment subprotocol\n* Patients must fulfill all eligibility criteria of MATCH Master Protocol at the time of registration to treatment step (Step 1, 3, 5, 7)\n* Patients must have mutations in the PTEN gene with 1% or more expression of PTEN by immunohistochemistry (IHC) as determined via the MATCH Master Protocol\n\n  * NOTE: For patients entering the study, all patients must have PTEN IHC performed as described in the MATCH Master Protocol. This includes patients entering the study via the outside assay process\n* Patients must not have co-existing aberrations in the MAPK or PI3K/MTOR pathways as determined by the MATCH screening assessment in NRAS, HRAS, KRAS, BRAF, PIK3CA, AKT or mTOR\n* Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment assignment and must have no clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, third degree heart block)\n* Patients must not have known hypersensitivity to copanlisib or compounds of similar chemical or biologic composition\n* Patients must not have had prior treatment with copanlisib or other PI3K inhibitors, AKT inhibitors or mTOR inhibitors\n* Patients must not be on strong inhibitors or inducers of CYP3A4 within two weeks prior to start of study treatment and for the duration of study treatment\n* Patients should stop using herbal medications at least 7 days prior to the first dose of copanlisib. Herbal medications include, but are not limited to: St. John's wort, kava, ephedra, gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, black cohosh and ginseng\n* Patients with type I or II diabetes mellitus must have a glycosylated hemoglobin (HbA1c) ≤ 8.5% within 28 days from registration\n* Patients must not have uncontrolled hypertension defined as systolic blood pressure (SBP) greater than 160 mmHg or diastolic blood pressure (BP) greater than 100 mmHg or use of more than 2 anti-hypertensive medications\n* Patients must not have HER2 positive (3+ by IHC or fluorescence in situ hybridization [FISH] ratio ≥ 2) breast cancer\n* Patients must not have indolent NHL (non-Hodgkin's lymphoma) or DLBCL (diffuse large B cell lymphoma) because other studies are ongoing with this agent in this group of patients\n* Patients must not be on anti-arrhythmic therapy other than digoxin or beta-blockers\n* Absoulute neutrophil count (ANC) ≥ 1.5 x 10^9 /L\n* Platelets ≥ 100 x10^9 /L\n* Hemoglobin (Hb) > 9 g/dl\n* Total serum bilirubin < 2.0 mg/dL\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5x upper limit of normal (ULN) (< 5 x ULN in patients with liver metastases)\n* Serum creatinine < 1.5 x ULN\n* Patients with non-healing wound, ulcer, or bone fracture are not eligible\n* Patients with history of or current interstitial pneumonitis are not eligible\n\n  * NOTE: For solid tumors, cytomegalovirus (CMV) polymerase chain reaction (PCR) can be obtained at the discretion of treating physician or local institutional guidelines\n* Men and women of child-bearing potential must agree to use contraception while receiving study treatment and for 1 month after the last dose of copanlisib\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}